The Need

The current global landscape demands innovative solutions to address the urgent need for a safe and efficacious SARS-CoV-2 vaccine, particularly for the vulnerable population of infants and children under 12 years old. Existing vaccines face challenges in terms of durability, cost, and stability, with a pressing necessity to enhance protection against emerging variants, notably the delta variant. The demand for a reliable, accessible, and durable vaccine solution is more critical than ever to alleviate the economic, emotional, and public health burdens caused by the ongoing pandemic.

The Technology

Presenting a groundbreaking solution, our trivalent recombinant mumps virus (rMuV)-based and measles virus (MeV)-based SARS-CoV-2 vaccines provide a cutting-edge approach to COVID-19 vaccination. Developed with advanced methods, these vaccines offer a promising avenue to overcome the limitations of existing options. The trivalent formulation ensures a comprehensive immune response, and the innovative technology addresses the critical challenges posed by the current pandemic.

Commercial Applications

• Vaccination for infants and children under 12 years old: Filling a crucial gap in the market, our technology provides a safe and effective SARS-CoV-2 vaccine specifically designed for the younger population.
• Boosting immunity against emerging variants: Our trivalent vaccines offer enhanced protection, addressing concerns related to the reduced efficacy of existing vaccines against novel variants of concern.
• Cost-effective and accessible vaccination: The technology aims to reduce production, transportation, and storage costs, making vaccination programs more feasible and widespread.

Benefits/Advantages

• Comprehensive immune response: The trivalent formulation, utilizing recombinant mumps and measles viruses, ensures a robust and multi-faceted defense against SARS-CoV-2.
• Improved durability: Overcoming the limitations of current vaccines, our technology aims to provide longer-lasting protection, minimizing the need for frequent booster doses.
• Enhanced stability and accessibility: By utilizing innovative platforms, our vaccines streamline production and distribution processes, offering a stable and accessible solution for global vaccination campaigns.

In summary, our trivalent recombinant mumps virus (rMuV)-based and measles virus (MeV)-based SARS-CoV-2 vaccines address critical gaps in the market, providing a timely, advanced, and comprehensive solution to the pressing challenges posed by the current pandemic.